The Patient Billing War Nobody Is Talking About
Waystar has spent years building what most hospital CFOs would call the default choice for revenue cycle management – a sprawling, enterprise-grade platform that handles everything from claims processing to payment posting. But a quieter competitor has been doing something Waystar’s architecture was never really designed to prioritize: making the patient financial experience feel less like a collections notice and more like a checkout flow. Cedar, the patient financial engagement platform backed by Andreessen Horowitz and Thrive Capital, is not trying to replace Waystar outright. It is inserting itself between the hospital and the patient in ways that are starting to matter more than the underlying billing infrastructure itself.
The distinction sounds subtle. It is not. As hospitals face mounting pressure from patient satisfaction scores tied to reimbursement rates and growing bad debt from high-deductible health plans, the front end of the billing experience has become a genuine competitive battleground. Cedar’s bet is that a consumer-grade payment layer – one that sends personalized text messages, offers flexible payment plans, and explains bills in plain language – can generate more collected revenue than legacy clearinghouse platforms optimized for payer transactions rather than patient ones. Health systems across the country are starting to agree.
What Cedar Is Actually Selling
Cedar does not position itself as a revenue cycle management company in the traditional sense. It describes itself as a patient financial engagement platform, which is a careful and deliberate framing. The company integrates on top of existing electronic health record systems and billing platforms rather than replacing them, meaning hospitals do not have to rip out their Waystar or Epic connections to bring Cedar in. That integration strategy has been central to Cedar’s growth – it removes the biggest objection a CFO would otherwise raise.
The core product is a billing experience delivered primarily through mobile-optimized web links sent via text message. When a patient receives a bill, Cedar’s platform personalizes the communication based on the patient’s history, outstanding balance, and predicted ability to pay. The system can automatically segment patients into payment plan tiers, flag accounts likely to need charity care screening, and A/B test messaging to improve conversion rates on outstanding balances. These are things Waystar’s core platform was not built to do because Waystar was built around the payer relationship, not the patient relationship.
Where this gets genuinely disruptive is in the numbers that health systems are reporting internally. Cedar has publicly cited collection rate improvements in the range of 30 percent over legacy billing methods for some of its health system clients, though individual results vary. What those improvements represent in practice is a meaningful shift in how hospital finance teams think about vendor priority. When a billing platform demonstrably moves revenue, budget conversations change.
Where Waystar Is Exposed
Waystar’s strength has always been on the payer side of the equation – eligibility checks, claim scrubbing, denial management, remittance processing. That suite of capabilities is genuinely difficult to replicate and represents years of payer contracting relationships and clearinghouse infrastructure. But the patient responsibility portion of hospital revenue has grown sharply as high-deductible health plans became the norm across employer-sponsored insurance markets. Patient collections now represent a much larger slice of total hospital revenue than they did a decade ago, and that is precisely the segment where Waystar’s toolset is weakest.
Waystar has patient engagement features, but they were added onto a platform designed for B2B transaction flows, not consumer behavior patterns. Cedar was built from the start with consumer product sensibilities – its founders came from fintech and consumer technology backgrounds rather than healthcare IT. That origin matters because the product reflects it. Cedar’s interface looks and behaves more like a Venmo payment screen than a traditional patient portal, and for patients who are already accustomed to mobile-first financial experiences, that difference in feel translates directly into payment completion rates. Waystar can close that gap through acquisition or development, but it is currently running behind on the experience layer that health systems are increasingly using as a decision criterion.
The Health System Calculation
For hospital CFOs, the vendor evaluation logic is not complicated. If Cedar can demonstrably collect more money from patients than the existing billing workflow, the ROI calculation closes quickly – even if Cedar represents an additional line item in the vendor budget. Cedar typically charges on a performance basis or as a percentage of collections, which means health systems are not paying for the platform unless it is working. That pricing model removes a significant adoption barrier and aligns Cedar’s incentives directly with hospital finance teams.
The strategic risk for Waystar is not that Cedar replaces its clearinghouse functionality – that is not what Cedar is selling. The risk is that Cedar becomes the primary relationship layer between the hospital and the patient, making Waystar increasingly invisible infrastructure. In technology markets, invisible infrastructure eventually becomes commoditized infrastructure. If health systems begin evaluating their revenue cycle stack by asking “what is our patient experience layer” rather than “what is our RCM platform,” Cedar wins the branding and relationship battle even when Waystar is still doing the transaction processing underneath.
There is also a data angle that rarely gets discussed in coverage of this space. Cedar sits at the point of patient financial contact, which means it accumulates behavioral data about how patients respond to billing communications, payment plan structures, and financial assistance messaging. Over time, that dataset becomes a genuine product moat. Cedar can train predictive models on what messaging converts, what payment thresholds trigger plan enrollment, and which patient populations have the highest bad debt risk – and offer those insights back to health systems as an analytics layer. Waystar does not have comparable consumer behavioral data because its platform was never consumer-facing in that way.
Cedar has already signed partnerships with major health systems including Mount Sinai Health System and Advocate Aurora Health, which signals that the platform is past the early-adopter stage and into mainstream enterprise deployment. These are not pilot programs. They are production billing environments for systems processing millions of patient encounters annually. At that scale, Cedar’s integration depth with hospital workflows becomes a switching cost of its own – the same dynamic that once locked hospitals into Waystar now starts working in Cedar’s favor.
Waystar is not standing still. The company went public in 2024, giving it capital to invest in product development and acquisitions. But going public also means Waystar is now accountable to quarterly earnings expectations, which can compress the appetite for the kind of long-cycle product rebuilding that closing the patient experience gap would require. Cedar, still operating with venture backing and a growth mandate, does not have that constraint. The question is not whether Waystar can eventually build a competitive patient engagement product – it probably can. The question is whether the health systems currently in contract renewal cycles are willing to wait for it.
